Armata Pharma: Up on FDA nod for human trial of bacterial infections treatment

Armata Pharmaceuticals

15/10/2020 14:39

** Shares of drug maker  ARMP.A  rise 20% to $3.8 - set for
best day in 7 months
    ** Co says U.S. FDA has cleared its application to start
clinical trial of its lead candidate AP-PA02 to treat
Pseudomonas aeruginosa infections  urn:newsml:reuters.com:*:nPn9SNV4da
    ** Pseudomonas aeruginosa is bacterium found in hospitals
and resistant to many antibiotic treatments
    ** Co expects to begin trials by year-end
    ** Up to Wednesday's close, stock had fallen 1.2% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))